Schizophrenia and Co-Occurring Substance Use Disorder

Support for this model has been found in studies indicating that substance abuse is associated with an earlier age at onset of schizophrenia (2, 3), the recent finding that use of cannabis by adolescents who have the "high output" catechol O-methyltransferase polymorphism (Val/Val) is asso...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of psychiatry 2007-03, Vol.164 (3), p.402-408
Main Authors: Green, Alan I., Drake, Robert E., Brunette, Mary F., Noordsy, Douglas L.
Format: Article
Language:English
Subjects:
Addictive behaviors
Adult
Adult and adolescent clinical studies
Alcohol use
Alcohol-Related Disorders - drug therapy
Alcohol-Related Disorders - epidemiology
Antipsychotic Agents - therapeutic use
Biological and medical sciences
Brain
Chronic illnesses
Comorbidity
Diagnosis, Dual (Psychiatry)
Disulfiram - therapeutic use
Drug abuse
Drug addiction
Homeless Persons - psychology
Hospitalization
Humans
Infectious diseases
Male
Medical sciences
Naltrexone - therapeutic use
Physical examinations
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Psychotropic drugs
Risk factors
Schizophrenia
Schizophrenia - diagnosis
Schizophrenia - drug therapy
Schizophrenia - epidemiology
Side effects
Substance-Related Disorders - diagnosis
Substance-Related Disorders - drug therapy
Substance-Related Disorders - epidemiology
Taurine - analogs & derivatives
Taurine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Support for this model has been found in studies indicating that substance abuse is associated with an earlier age at onset of schizophrenia (2, 3), the recent finding that use of cannabis by adolescents who have the "high output" catechol O-methyltransferase polymorphism (Val/Val) is associated with a higher risk of developing psychosis in young adulthood (B), and evidence that patients with schizophrenia experience negative clinical effects, such as relapse, after using small quantities of substances of abuse (9). Co-occurring substance use disorders are often underdetected and undertreated in mental health settings, where the traditional separation between mental health and substance abuse training programs and service delivery systems results in a lack of knowledge about co-occurring disorders and a seemingly inconsistent commitment to the treatment of the substance abuse component.
ISSN:0002-953X
1535-7228
DOI:10.1176/ajp.2007.164.3.402